Warning: count(): Parameter must be an array or an object that implements Countable in /home/customer/www/drugtrialsformoney.com/public_html/wp-content/plugins/redux-framework/redux-core/inc/classes/class-redux-output.php on line 373

ISPY-P1.01:Evaluating the Safety of Weekly Paclitaxel With Trastuzumab Duocarmazine (SYD985) in Patients With Metastatic Cancer

ISPY-P1.01:Evaluating the Safety of Weekly Paclitaxel With Trastuzumab Duocarmazine (SYD985) in Patients With Metastatic Cancer
Conditions:   HER2-positive Breast Cancer;   HER2 Low;   SYD-985;   SYD985;   Vic-trastuzumab Duocarmazine;   Metastatic Cancer;   Metastatic Breast Cancer;   Metastatic Gastrointestinal Carcinoid Tumor;   Metastatic;   HER2 Low Breast Cancer;   GastroEsophageal Cancer;   Gastroesophageal Adenocarcinoma;   Endometrium Tumor;   Ovarian Cancer;   Ovarian Carcinoma;   Urothelial Carcinoma;   Urothelial Tumor;   HER2-positive Gastric Cancer;   HER2-positive Metastatic Breast Cancer;   HER2 Mutation-Related Tumors;   HER-2 Protein Overexpression;   HER2 Low HR Positive;   HR Positive;   Hormone Receptor-positive Breast Cancer;   Estrogen Receptor Positive Tumor;   Progesterone Receptor-positive Breast Cancer;   Triple Negative Breast Cancer;   Hormone Receptor Negative Breast Carcinoma
Intervention:   Drug: Vic-trastuzumab duocarmazine (SYD985) + paclitaxel
Sponsors:   QuantumLeap Healthcare Collaborative;   Byondis B.V.
**RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

October 19, 2021 / by / in
Comments